Sign In
Buy RLYB
$16.07
-0.160 (-0.99%)
At Close: Jun 03, 2026
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
08:00am, Thursday, 09'th Nov 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corp
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study ha
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
08:00am, Tuesday, 03'rd Oct 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio: Gearing Up To Be An Opportunity
05:15pm, Friday, 15'th Sep 2023
Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in pa
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio to Present at Upcoming Investor Conferences in September
08:00am, Thursday, 31'st Aug 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
11:05am, Monday, 29'th May 2023
The mean of analysts' price targets for Rallybio Corporation (RLYB) points to a 202.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Rallybio to Present at Upcoming Investor Conferences in March
08:00am, Wednesday, 01'st Mar 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
08:00am, Tuesday, 29'th Nov 2022
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapie
Rallybio to Present at Upcoming Investor Conferences in November
08:00am, Friday, 11'th Nov 2022
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapie
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
08:00am, Wednesday, 31'st Aug 2022
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies
Rallybio (RLYB) Investor Presentation - Slideshow
06:19pm, Friday, 11'th Mar 2022 Seeking Alpha
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
01:00pm, Monday, 28'th Feb 2022 Business Wire
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET. A webcast of the panel discus
Rallybio Corp Shares Close the Day 10.1% Higher - Daily Wrap
11:01am, Sunday, 09'th Jan 2022 Kwhen Finance
Rallybio Corp (RLYB) shares closed today 10.1% higher than it did at the end of yesterday. The stock is currently up 3.9% year-to-date, down 29.7% over the past 12 months, and down 29.7% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $10.97 and as low as $8.06 this week.Shares closed 61.6% below its 52-week high and 23.0% above its 52-week low.Trading volume this week was 53.9% lower than the 10-day average and 53.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1588.2% The company's stock price performance over the past 12 months lags the peer average by 239.6%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
